DURECT Corp DRRX Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 13, 2023 (filed on Mar 15, 2023)

Insider Name:

Bleichroeder LP

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

-3,498

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Sussman Norman

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

24,557

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Sussman Norman

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

45,000

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Papp Timothy M.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,377

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Papp Timothy M.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

60,000

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Joice Judy R

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

17,456

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Joice Judy R

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Brown James E

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,665

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Brown James E

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

200,000

Price:

--
Aug 19, 2022 (filed on Aug 22, 2022)

Insider Name:

Robertson Judith J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

9,412

Price:

$0.85

Filings by filing date

Mar 13, 2023 (filed on Mar 15, 2023)

Insider Name:

Bleichroeder LP

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

-3,498

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Sussman Norman

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

24,557

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Sussman Norman

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

45,000

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Papp Timothy M.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,377

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Papp Timothy M.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

60,000

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Joice Judy R

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

17,456

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Joice Judy R

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Brown James E

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

50,665

Price:

--
Feb 21, 2023 (filed on Feb 23, 2023)

Insider Name:

Brown James E

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

200,000

Price:

--
Aug 19, 2022 (filed on Aug 22, 2022)

Insider Name:

Robertson Judith J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

9,412

Price:

$0.85

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	10260 Bubb Rd CUPERTINO CA 95014
Tel:	1-646-3782928
Website:	https://www.durect.com
IR:	See website

Key People

James E. Brown President, Chief Executive Officer, Director	Timothy M. Papp Chief Financial Officer, Company Secretary	Judy R. Joice Senior Vice President - Operations and Corporate Quality Assurance
Norman L. Sussman Chief Medical Officer

Business Overview

Durect Corporation is a biopharmaceutical company that is focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company's other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The Company is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The Company focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug. CLOUD is a class of bioerodible injectable depot technology.

Financial Overview

For the three months ended 31 March 2023, DURECT Corp revenues increased 7% to $2.1M. Net loss increased 11% to $12M. Revenues reflect Europe segment increase of 28% to $431K, United States segment increase of 6% to $1.3M. Higher net loss reflects Other Research and development increase of 5% to $8.3M (expense), Selling and general increase of 12% to $3.8M (expense).

Employees:	75 as of Mar 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$118.02M as of Mar 31, 2023
Annual revenue (TTM):	$19.42M as of Mar 31, 2023
EBITDA (TTM):	-$35.58M as of Mar 31, 2023
Net annual income (TTM):	-$36.48M as of Mar 31, 2023
Free cash flow (TTM):	-$30.06M as of Mar 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	24,489,843 as of May 3, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization